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Abstract
Introduction Survival benefit from ICD implantation is rela-
tively low in primary prevention patients. Better patient selec-
tion is important to maintain maximum survival benefit while
reducing the number of unnecessary implants. Microvolt T-
wave alternans (MTWA) is a promising risk marker. In this
study, we aimed to evaluate the predictive value of MTWA in
ICD patients.
Methods and results This study was a substudy of the Twente
ICD Cohort Study (TICS). Patients with ischaemic or non-
ischaemic left ventricular dysfunction who received an ICD
following current ESC guidelines were eligible for inclusion.
Exercise-MTWA was performed and classified as non-
negative or negative. The primary endpoint was the composite
of mortality and appropriate shock therapy. Analysis was
performed in 134 patients (81 % male, mean age 62 years,
mean ejection fraction 26.5 %). MTWAwas non-negative in
64 %. There was no relation between non-negative MTWA
testing and mortality and/or appropriate shock therapy (all p-
values >0.15). Due to clinical conditions, 24%were ineligible
for testing. These patients experienced the highest risk for
mortality (p<0.01).
Conclusion Non-negative MTWA testing did not predict mor-
tality and/or appropriate shock therapy. Furthermore, MTWA
testing is not feasible in a large percentage of patients. These
ineligible patients experience the highest risk for mortality.
Keywords Microvolt Twave alternans . Implantable
cardioverter defibrillator . Prognostic value .Mortality .
Cardiomyopathy . Risk stratification
Introduction
Several primary and secondary prevention trials have
established the beneficial role of implantable cardioverter
defibrillator (ICD) therapy in preventing sudden cardiac death
(SCD) [1–6]. Therefore, the guidelines indicate ICD implan-
tation in both survivors of cardiac arrest (secondary preven-
tion) and in patients who are at high risk of developing life-
threatening ventricular arrhythmias (primary prevention) [7].
Nevertheless, only a minority of patients will experience
life-threatening ventricular arrhythmias (VA) necessitating
ICD therapy, this being even more prominent in primary
prevention patients [5, 6, 8, 9]. Improved patient selection is
important to maintain maximum survival benefit of ICD im-
plantation while reducing the number of unnecessary
implants.
Microvolt T-wave alternans (MTWA) is a promising elec-
trocardiographic risk marker for predicting SCD and life-
threatening VA [10–14]. MTWA is a phenomenon of beat-
to-beat variability in the amplitude of the T-wave. The precise
underlying relation between MTWA and VA is not well
known. One hypothesis suggests that MTWA reflects spatial
and temporal heterogeneity or dispersion in the ventricular
repolarisation, which could lead to VA by means of formation
of functional re-entry circuits [15]. Despite conflicting results
regarding its predictive value and feasibility [16–20], MTWA
testing is currently incorporated in the guidelines as a diag-
nostic tool to improve risk stratification in patients with isch-
aemic and non-ischaemic severe left ventricular dysfunction
[7, 21].
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In this study, we aimed to prospectively evaluate the pre-
dictive value of MTWA in a real-life population of ICD
recipients.
Methods
Study design and patient enrolment
The Twente ICD Cohort Study (TICS; NL13939.044.06) is a
prospective single-centre observational study of ICD recipi-
ents, designed to evaluate the prognostic value of MTWA and
other potential arrhythmic risk factors in predicting mortality
and life-threatening VA. All consecutive patients between
September 2007 and March 2010 who received an ICD for
primary or secondary prevention of SCD according to the
ESC guidelines were eligible for inclusion in the TICS [7].
In the currently presented MTWA substudy, only patients with
ischaemic or non-ischaemic left ventricular dysfunction were
included. Ischaemic heart disease was defined as left ventric-
ular dysfunction associated with a documented history of
myocardial infarction, prior coronary artery bypass surgery,
prior percutaneous coronary intervention or significant
narrowing of at least one of the major coronary arteries. All
other cases were classified as non-ischaemic left ventricular
dysfunction. The choice and programming of the device were
left to the discretion of the implanting physician. Standard
settings for our centre are ventricular fibrillation (VF) zone
>230 beats per minute (bpm), and ventricular tachycardia
(VT) zone >185 bpm with antitachycardia pacing (ATP).
T-wave alternans testing
MTWA testing was performed in all patients in sinus rhythm.
Chronic medication, including beta-blockers, was continued
during MTWA testing. Careful skin preparation was per-
formed and high-resolution electrodes were used to minimise
noise. In addition to the standard 12-lead ECG, three orthog-
onal X, Yand Z leads were recorded as well. Measurements
were made with a HeartTWave system II (Cambridge Heart
Inc., Bedford, Massachusetts, USA) using the spectral analy-
sis method during exercise. After gradually increasing the
workload to achieve a constant heart rate, a target heart rate
between 100 and 110 bpm was attained and kept stable for
2.5 min. Subsequently, during 1.5 min, a target heart rate
between 110 and 120 bpm was maintained. The result of the
MTWA test was automatically interpreted by the Alternans
Report Classifier within the system and carefully reviewed by
trained physicians. Each MTWA report was classified posi-
tive, indeterminate or negative using accepted criteria [22, 23].
A test was defined positive if the MTWAvoltage was ≥1.9 μV
for at least 1 min with an onset heart rate <110 bpm or at rest in
any of three orthogonal leads (X, Yor Z), or in two adjacent
precordial leads. If the recording did not prove positive and
the heart rate was >105 bpm for at least one minute, the
MTWA test was defined as negative. An MTWA test was
considered indeterminate if the test did not meet the criteria for
being classified as positive or negative. Based on prior litera-
ture about further analysis, patients with indeterminate or
positive tests were combined as non-negative MTWA [24].
Follow-up and endpoints
All patients were followed on a regular basis (every 3–
6 months) in our outpatient ICD clinic, either by visits or
telemonitoring. All ICD data were obtained by interrogation
of the device.
The primary endpoint was the combined endpoint of all-
cause mortality and appropriate ICD shock therapy for VTor
VF. Secondary endpoints were all-cause mortality and appro-
priate ICD shock therapy for VTor VF.
Statistical analysis
Continuous variables are presented as mean±SD, and cate-
gorical data are summarised as frequencies and percentages.
Differences in baseline characteristics between MTWA posi-
tive and negative patients were analysed using Student’s t-test
or the Mann–Whitney U-test, as appropriate, if continuous, or
chi-square or Fisher’s exact test if categorical. Unless other-
wise specified, p-values and confidence intervals (CIs) were
two-sided and a p-value <0.05 was considered significant.
Univariate and multivariate logistic regression analyses
were performed to evaluate MTWA as an independent predic-
tor of mortality and/or appropriate shock. All variables were
evaluated by univariate analysis as possible predictors, and
only those with a significance at or below p=0.15 were
analysed using multivariate logistic regression analysis.
Results
Patients
From September 2007 until March 2010, 503 patients re-
ceived an ICD. Of these patients, 300 were included in the
TICS. In all the other patients, no informed consent was
obtained. Of these 300 patients, 269 patients with ischaemic
or non-ischaemic left ventricular dysfunction were eligible for
this MTWA substudy. MTWA testing was performed in 134
of 269 (49.6 %) patients. In 62 of 269 (23.0 %) patients
MTWA was not performed due to logistic reasons (mainly
secondary prevention ICD recipients who received their ICD
during hospitalisation), 7 of 269 (2.6 %) patients refused to
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participate and 66 of 269 (24.5%) patients were not capable of
performing exercise-based MTWA testing.
In the 134 tested patients (81 % male, mean age 62 years,
mean left ventricular ejection fraction (LVEF) 26.5 %),
MTWAwas positive in 48 (35.8 %) patients, negative in 48
(35.8 %) patients and indeterminate in 38 (28.3 %) patients
(due to noise (9 (6.7 %) patients), frequent ventricular or atrial
ectopy (15 (11.2 %) patients), or not achieving the target heart
rate (14 (10.4 %) patients). Positive and indeterminate results
were combined in the non-negative group. The clinical char-
acteristics are presented in Table 1. Among patients with a
non-negative test result, significantly more were male and had
wider QRS duration. There was a trend for association be-
tween lower LVEF and non-negative MTWA.
Clinical outcome
During a mean follow-up of 38±10 months, 21 patients
(15.6 %) reached the primary endpoint of death (10 (7.5 %)
patients) and/or appropriate shock therapy (11 (8.2 %)
patients).
Predictors for the combined endpoint of mortality and
appropriate shocks (Table 2) were wider QRS duration (p=
0.03) and chronic obstructive pulmonary disease (p=0.01).
No significant relation was found between non-negative
MTWA testing and the primary endpoint (p=0.58, Fig. 1).
Ischaemic left ventricular dysfunction was present in 87
(64.9 %) patients, of whom 53 (60.9 %) had a non-negative
test result. Non-ischaemic left ventricular dysfunction was
present in 47 (35.1 %) patients, of whom 33 (70.2 %) had a
non-negative test result. MTWAwas neither predictive for the
combined endpoint of death and/or appropriate shock in isch-
aemic or non-ischaemic LV dysfunction (all p-values >0.66).
Regarding the secondary endpoint mortality, significant
associations were found with lower LVEF (p=0.03), chronic
obstructive pulmonary disease (p=0.05), NYHA functional
class≥3 (p=0.02), non-negative MTWA (p=0.05, Fig. 1) or
QRS duration (p=0.03). After constructing a multivariate
model using these parameters, multivariate analysis showed
that MTWAwas no longer an independent predictor (p=0.15).
In the patients with ischaemic left ventricular dysfunction, 6
(6.9 %) patients died, all in the non-negative MTWA group.
Using Kaplan-Meier survival analysis, a significant relation
between non-negative MTWA and mortality was found (p=
0.04). Other significant univariate variables were lower LVEF
and wider QRS duration. After correction using multivariate
regression analysis, non-negative MTWA lost its significance.
In the non-ischaemic LV dysfunction group, 5 (10.6 %)
Table 1 Clinical characteristics
*p<0.05 and **p<0.01 in com-
parison with TWA negative group
LVEF left ventricular ejection
fraction, DM diabetes mellitus,
COPD chronic obstructive pul-
monary disease, CVA cerebrovas-
cular accident, TIA transient isch-
aemic attack, AF atrial fibrillation,
ACEi angiotensin-converting en-
zyme inhibitor, ARB angiotensin
receptor blocker, NYHA New
York Heart Association
All Negative Non-negative Ineligible
Number of patients 200 48 86 66
General
Age (years±SD) 63.0 (10.3) 59.8 (11.9) 63.0 (9.5) 65.8 (9.8)**
Gender (male) 170 (84.6) 33 (68.8) 75 (87.2)* 62 (93.9)**
LVEF (%±SD) 26.7 (12.2) 29.1 (13.1) 25.0 (11.2) 27.0 (12.8)
Comorbidities
Hypertension 53 (26.4) 12 (25.0) 24 (27.9) 18 (27.3)
DM 47 (23.4) 11 (22.9) 14 (16.3) 22 (33.3)
COPD 21 (10.4) 2 (4.2) 11 (12.8) 7 (10.6)
CVA/TIA 14 (7.0) 3 (6.2) 4 (4.7) 7 (10.6)
AF 52 (25.9) 5 (10.4) 9 (10.5) 40 (60.6)**
Indication
Primary 161 (80.5) 38 (79.2) 74 (86.0) 49 (74.2)
Secondary 39 (19.5) 10 (20.8) 12 (14.0) 17 (25.8)
Aetiology
Ischaemic 135 (67.2) 34 (70.8) 53 (61.6) 48 (74.2)
Dilated 66 (32.8) 14 (29.2) 44 (38.4) 17 (25.8)
Medication
Beta-blocker 169 (84.1) 42 (87.5) 70 (81.4) 55 (83.3)
ACEi/ARB 169 (84.1) 50 (83.3) 75 (87.2) 53 (80.3)
Diuretics 153 (76.1) 32 (66.7) 66 (76.7) 55 (83.3)*
Amiodarone 20 (10.0) 4 (8.3) 6 (7.0) 10 (15.2)
NYHA functional class ≥3 53 (26.8) 7 (14.6) 18 (21.2) 29 (45.3)**
QRS duration (ms±SD) 125 (31) 115 (30) 125 (28) 131 (34)*
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patients died, four in the non-negative group and one in the
negative group. No relation was found between MTWA and
mortality (p=0.55).
Appropriate shock therapy as alternative secondary end-
point occurred in 11 (8.2 %) patients, 5 (5.8 %) patients with a
non-negative MTWA and 6 (12.5 %) patients with a negative
MTWA (p=0.19, Fig. 1). In the patients with ischaemic left
ventricular dysfunction, 8 (9.2 %) patients experienced appro-
priate shock therapy. Three (37.5 %) patients had a non-
negative test, and 5 (62.5 %) had a negative test (p=0.14).
In the patients with non-ischaemic LV dysfunction, 3 (6.3 %)
patients experienced appropriate shock therapy. Two events
(66 %) occurred in patients with a non-negative test result
whereas 1 (33 %) patient with a negative test result experi-
enced appropriate therapy (ns, p=0.97).
Ineligible patients
In 66 of 269 (24.5 %) patients, MTWA by means of exercise
stress testing was technically not feasible because of atrial
fibrillation (n=43), pacemaker-dependency (n=8), or clinical
state (n=15). Ineligible patients were more frequently male
(p=0.01), older (p<0.01), more often known with atrial fibril-
lation (p<0.001), and a lower functional class (p<0.001). The
combined primary endpoint of mortality and appropriate
shock was reached in 26 (39.4 %) patients. This was signifi-
cantly higher than in the non-negative (RR 2.5 (95 % CI 1.3-
4.7) p<0.01) and negative (RR 3.3 (95%CI 1.4-7.6), p<0.01)
MTWA group. After multivariate correction for confounders,
ineligibility for TWA testing remained the only significant
predictor of the combined endpoint of mortality and appropri-
ate shock therapy (Fig. 1).
Regarding the secondary endpoints, compared with non-
negative patients, ineligible patients experienced both higher




Age 1.03 (0.99–1.07) 0.16
Male gender 1.13 (0.42–3.04) 0.89
LVEF 0.99 (0.96–1.03) 0.67
Comorbidities
Hypertension 0.54 (0.18–1.59) 0.26
DM 1.25 (0.46–0.37) 0.66
COPD 3.47 (1.36–8.84) 0.01
CVA/TIA 0.04 (0.00–64.08) 0.40
AF 1.51 (0.45–5.10) 0.50
Prophylactic indication 0.55 (0.22–1.39) 0.21
Ischaemic cardiomyopathy 0.74 (0.33–1.69) 0.47
NYHA functional class ≥3 1.22 (0.45–3.30) 0.69
QRS duration (ms±SD) 1.01 (1.00–1.03) 0.03
Non-negative MTWA 1.29 (0.53–3.13) 0.58
Hazard ratio (±95 % CI). Hazard ratio for age per 1 year increase in age.
Hazard ratio for LVEF per 1 % increase in LVEF. Hazard ratio for QRS
duration per 1 ms increase in duration
LVEF left ventricular ejection fraction, DM diabetes mellitus, COPD
chronic obstructive pulmonary disease, CVA cerebrovascular accident,
TIA transient ischaemic attack, AF atrial fibrillation, ACEi angiotensin-
converting enzyme inhibitor, ARB angiotensin receptor blocker, NYHA
New York Heart Association
Fig. 1 Survival curves regarding the role of MTWA in predicting a
mortality and/or appropriate shock therapy, b mortality and c appropriate
shock therapy
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rates of mortality (p=0.01, Fig. 1) and appropriate shocks (p=
0.01, Fig. 1).
Recently, doubt has been raised about the feasibility of
MTWA testing in potential ICD recipients [18]. In our study,
MTWA testing was not technically feasible in 24.5 % of
included patients. In the literature, percentages between 35
and 49% can be found [18–20]. If testing in ineligible patients
is mandatory, MTWA can be assessed using a protocol based
on pacing or pharmacological increase of heart rate. These
protocols, however, are not useable in patients with atrial
fibrillation or other irregular heart rhythms, but are very useful
for patients who cannot reach the target heart rate. Concor-
dance between these different protocols varies between 55 and
98 % [25–29]. Not much is known about the prognostic value
of pacing-based MTWA. Rashba et al. found no relation with
death, sustained ventricular arrhythmia or appropriate ICD
therapy using an atrial paced protocol [26]. No data are
reported on the prognostic value of ventricular pacing-based
protocols or pharmacological intervention protocols to in-
crease heart rate.
The question remains whether these patients need to be
tested by means other than exercise stress testing MTWA
protocols since in both our study and the studies by Shizuta
and Jackson, patients in whom exercise-based MTWA testing
is not possible experience the highest risk of mortality and VA
requiring ICD therapy, which remains statistically significant
after correction for possible confounders [19, 20].
Limitations
The main limitation of this trial is the number of patients in
combination with the low event rate. The study is therefore
relatively underpowered and caution is required when
interpreting the results.
Conclusion
In the present study, we did not find a significant relation
between non-negative MTWA testing and mortality or appro-
priate shock therapy. Its role in the selection of ICD patients
therefore remains controversial. Furthermore, MTWA testing
is not feasible in a large percentage of patients. These ineligi-
ble patients experience the highest risk for mortality or appro-
priate ICD therapy.
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